Testing a breath marker to guide care for newborn jaundice
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at a breath-related measurement (from the air you exhale) to help diagnose and guide treatment for jaundice in certain newborns. It may help the care team better decide what care you need after birth, especially when jaundice is related to blood type mismatch.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Babies must be born at 35 weeks 0 days through 41 weeks 6 days
- Birth weight must be at least 2500 grams
- Your baby’s breathing rate must be under 60 breaths per minute
- Baby is admitted to the newborn unit for light therapy (phototherapy) for high bilirubin (jaundice)
- Jaundice must be linked to mother-and-baby blood type mismatch (ABO incompatibility)
- A parent/guardian must sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a simple breath test to measure carbon monoxide levels in newborns, which may help doctors better manage jaundice. It aims to understand how these levels change and how they relate to jaundice treatment.
This trial uses a special breath test (ETCOc) to measure jaundice in newborns, aiming to improve diagnosis and treatment. It may help doctors decide when treatment is needed.
This study tests a new method to measure how much fetal blood leaks into the mother's bloodstream, which can cause severe jaundice in newborns. It may help doctors diagnose hemolytic disease of the newborn earlier and more accurately.
This trial studies if a blood test measuring the ratio of two proteins can better predict brain damage from severe jaundice than the current standard test. It aims to help doctors identify babies who need faster treatment.
This study tests a device that measures jaundice (yellowing of the skin) through the skin rather than with a blood test. It may help newborns avoid a needle stick.
This trial checks whether a new device can accurately detect and track yellowing of the skin (newborn jaundice) in hospitals with limited resources. It may help clinicians monitor jaundice and decide on treatments like blue light therapy more reliably.
Hear when a new ABO Hemolytic Disease of Newborn trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.